FTSE MIB
33.746,66 -549,65 (-1,60%) Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.274,05 -131,61 (-0,34%) Petrolio
79,21 -2,72 (-3,32%) Bitcoin EUR
53.346,16 -2.318,59 (-4,17%)
Archer Materials Limited (ARRXF)
| Chiusura precedente | 0,3200 |
| Aperto | 0,3634 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 0,3200 - 0,3200 |
| Intervallo di 52 settimane | 0,1750 - 0,5050 |
| Volume | |
| Media Volume | 1.921 |
| Capitalizzazione | 84,442M |
| Beta (5 anni mensile) | 1,28 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0200 |
| Prossima data utili | 24 lug 2024 - 28 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireArcher’s biochip gFET design for advanced sensing validated by commercial foundry partner
Image 1 Archer’s advanced gFET chip for advanced biosensing diced from the whole four-inch wafer fabricated in a commercial foundry. Highlights Archer Materials’ commercial foundry partner in the Netherlands has validated its advanced biochip gFET design by manufacturing the chips using whole four-inch wafer semiconductor fabrication processes.The new gFET design for multiplexing was fabricated at a commercial scale foundry.The validation of the new advanced gFET device design and whole wafer ru
GlobeNewswireArcher further enhances biochip gFET design for advanced sensing and sends to commercial foundry partner
Highlights Archer Materials has advanced its biochip gFET design to improve its detection and control capabilities which link to the goal of single device multiplexing.The advanced gFET design is aimed at allowing the biochip to handle liquid samples to test for multiple diseases at once on a single chip, with potential for re-use capabilities.Archer has improved its biochip system capabilities towards automated data analysis so end users can extract high quality data with greater efficiency.The
- GlobeNewswire
Archer transfers biochip graphene sensor technology design to a commercial fab to verify scalability
Highlights Archer Materials has successfully completed a proof of concept biosensing graphene transistor for use in its biochip.The design has been submitted to a commercial foundry for a Multi-Project Wafer run.Fabrication at commercial foundries to verify the scalability of Archer’s design will occur in coming months with delivery of chips expected by the end of 2023.Archer has started discussions with potential global foundry partners for initial small production runs of its graphene chip des
